1. Home
  2. MLYS vs RDW Comparison

MLYS vs RDW Comparison

Compare MLYS & RDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$20.29

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Redwire Corporation

RDW

Redwire Corporation

HOLD

Current Price

$8.34

Market Cap

2.1B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
RDW
Founded
2019
2020
Country
United States
United States
Employees
N/A
1410
Industry
Biotechnology: Pharmaceutical Preparations
Military/Government/Technical
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.1B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
MLYS
RDW
Price
$20.29
$8.34
Analyst Decision
Strong Buy
Buy
Analyst Count
11
11
Target Price
★ $46.33
$14.28
AVG Volume (30 Days)
1.4M
★ 10.7M
Earning Date
11-09-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 37.43
2.98
EPS
N/A
★ N/A
Revenue
N/A
★ $335,381,000.00
Revenue This Year
N/A
$41.71
Revenue Next Year
N/A
$18.75
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 10.29
52 Week Low
$20.41
$4.87
52 Week High
$47.65
$26.64

Technical Indicators

Market Signals
Indicator
MLYS
RDW
Relative Strength Index (RSI) 32.24 29.78
Support Level N/A $7.69
Resistance Level $31.19 $10.43
Average True Range (ATR) 1.27 0.55
MACD -0.29 -0.23
Stochastic Oscillator 4.06 9.13

Price Performance

Historical Comparison
MLYS
RDW

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About RDW Redwire Corporation

Redwire Corp is an integrated space and defense technology company focused on technologies including aerospace infrastructure, autonomous systems and multi-domain operations, leveraging digital engineering and artificial intelligence automation. The Company develops and provides mission critical solutions based on space and defense technology platform offerings for government, commercial and civil customers through both short- and long-duration projects. These include technologies and production capability for next-generation spacecraft, large space infrastructure, microgravity capabilities, combat autonomous systems, optical sensors and radio frequency payloads that provide intelligence, surveillance, and reconnaissance capabilities for U.S. and allied nations across multiple domains.

Share on Social Networks: